Company intelligence / Profile preview
Laminar Pharma
Palma de Mallorca, Balearic Islands, Spainlaminarpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
LAM561 (idroxioleic acid/2-OHOA) is in Phase 2b/3 clinical trials for newly diagnosed glioblastoma in combination with standard of care. The company completed recruitment for the CLINGLIO trial in June 2024 and announced first open-label Progression-Free Survival data in March 2025. The drug has shown an outstanding safety profile with no serious adverse effects reported[1][3].
- Therapeutic areas
- Metabolic DisordersImmunologyOncologyRare DiseasesNeurology
- Modalities
- Synthetic lipidsMembrane lipid-targeting drugs
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Laminar Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Laminar Pharma.